<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00329914</url>
  </required_header>
  <id_info>
    <org_study_id>predict2006</org_study_id>
    <nct_id>NCT00329914</nct_id>
  </id_info>
  <brief_title>Does Progesterone Prevent Very Preterm Delivery in Twin Pregnancies?</brief_title>
  <official_title>Effectiveness of Vaginally Administered Progesterone to Prevent Preterm Delivery in Twin Pregnancies - A Multicentre Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Danish Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Danish Medical Society in Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AP Moeller Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether a daily dose of 200 mg progesterone
      administered vaginally from 20-23 to 34 weeks' gestation will reduce the rate of preterm
      delivery amongst twin pregnancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple gestations account for 2% of all pregnancies, but cause more than 10% of the cases
      of preterm delivery. Due to increasing maternal age and use of assisted reproduction the
      number of multiple gestations is larger than ever. If markers of preterm delivery can be
      identified and means of preventing preterm delivery are found, it will be possible to reduce
      the number of children admitted to hospital because of prematurity.

      Recently, two larger randomised studies investigated the effect of progesterone in singleton
      pregnancies of women who had previously delivered preterm. They both found a significant
      reduction in the preterm delivery rate in the progesterone group compared to a placebo group.

      The study will be performed as a randomized, double-blind placebo controlled study of twin
      pregnancies in Denmark and Austria. The women will be randomised in a 1:1 ratio to two groups
      (progesterone versus placebo). Randomisation will be stratified per centre and according to
      chorionicity, as the risk of preterm delivery is doubled in monochorionic twins compared to
      dichorionic twins.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of delivery &lt; 34 weeks, in the study group versus the control group</measure>
    <time_frame>Participants will be followed until 3 weeks after delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical and neurological development of the children at 6 and 18 months</measure>
    <time_frame>2 years after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship between cervical length and prophylactic progesterone treatment</measure>
    <time_frame>Participants will be followed until 3 weeks after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of proteomics and RNA in preterm delivery and term delivery and an evaluation of the effect of progesterone on proteomics and RNA</measure>
    <time_frame>Participants will be followed until 3 weeks after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the potential anti-inflammatory effect of progesterone by cytokine-measurements</measure>
    <time_frame>Participants will be followed until 3 weeks after delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the effect of progesterone on CRH-levels in twin pregnancies</measure>
    <time_frame>Participants will be followed until 3 weeks after delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">677</enrollment>
  <condition>Preterm Delivery</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Vaginal pessaries, 200 mg/day</description>
    <arm_group_label>Progesterone</arm_group_label>
    <other_name>Utrogestan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pessaries containing peanut oil</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Twin pregnancy

          -  Informed consent

          -  18-23 weeks' gestation

          -  Participants must be fluent in the language spoken in the respective centres

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Known allergy to progesterone or peanuts

          -  Active thromboembolic disorders or a history of hormone-associated thromboembolic
             disorders

          -  Rupture of membranes at the time of inclusion

          -  Monoamniotic twins

          -  Pregnancies treated for or with signs of twin-to-twin transfusion syndrome at
             inclusion

          -  Multiple pregnancies reduced to twin pregnancies

          -  Known significant structural or chromosomal fetal abnormality

          -  Chorionicity not assessed before 15 weeks

          -  Known or suspected malignancy in genitals or breasts

          -  Known liver disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Line Rode, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ultrasound Clinic 4002, Rigshospitalet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ann Tabor, professor</last_name>
    <role>Study Director</role>
    <affiliation>Ultrasound Clinic 4002, Rigshospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Graz University Hospital</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innsbruck University Hospital</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klagenfurt Hospital</name>
      <address>
        <city>Klagenfurt</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vienna University Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skejby Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glostrup Hospital</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hilleroed Hospital</name>
      <address>
        <city>Hilleroed</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holbaek Hospital</name>
      <address>
        <city>Holbaek</city>
        <zip>4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskilde Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soenderborg Hospital</name>
      <address>
        <city>Soenderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viborg Hospital</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT00329914</url>
  </link>
  <results_reference>
    <citation>Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A; PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol. 2011 Sep;38(3):272-80. doi: 10.1002/uog.9093.</citation>
    <PMID>21739497</PMID>
  </results_reference>
  <results_reference>
    <citation>Klein K, Rode L, Nicolaides KH, Krampl-Bettelheim E, Tabor A; PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high-risk twin pregnancies: secondary analysis of a placebo-controlled randomized trial and meta-analysis. Ultrasound Obstet Gynecol. 2011 Sep;38(3):281-7. doi: 10.1002/uog.9092.</citation>
    <PMID>21739499</PMID>
  </results_reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2006</study_first_submitted>
  <study_first_submitted_qc>May 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2006</study_first_posted>
  <last_update_submitted>July 22, 2011</last_update_submitted>
  <last_update_submitted_qc>July 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Professor Ann Tabor</name_title>
    <organization>Rigshospitalet</organization>
  </responsible_party>
  <keyword>Preterm delivery</keyword>
  <keyword>Prevention</keyword>
  <keyword>Twins</keyword>
  <keyword>Progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

